Oral #valganciclovir induction therapy for 14–21 days (1st line for newly dx, non-immediately sight-threatening #CMV #retinitis (peripheral lesion). High bioavailability & efficacy in preventing systemic CMV disease & contralateral eye involvement.
Induction is followed by lower-dose maintenance

👀 Now at #EDCTPForum, our colleage Vivian from #UZCRC is currently presenting her poster on "Pharmacokinetics and pharmacodynamics of ganciclovir in infants living with #HIV receiving #valganciclovir for #EMPIRICAL treatment of #CMV pneumonia in sub-Saharan Africa"

⬇️ Check out her results!